Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial.
de Velasco G, Carril-Ajuria L, Guerrero-Ramos F, Alonso-Gordoa T, Rodríguez-Moreno JF, Carretero A, Martin-Soberon M, de la Rosa-Kehrmann F, Castellano D. de Velasco G, et al. Oncotarget. 2020 Nov 24;11(47):4457-4462. doi: 10.18632/oncotarget.27807. eCollection 2020 Nov 24. Oncotarget. 2020. PMID: 33315988 Free PMC article.
A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01).
García-Donas J, Leon LA, Esteban E, Vidal-Mendez MJ, Arranz JA, Garcia Del Muro X, Basterretxea L, González Del Alba A, Climent MA, Virizuela JA, Álvarez C, Sepúlveda J, Anido U, López C, Ortiz-Morales MJ, Pérez X, Rodriguez-Antona C, Rodriguez-Moreno JF, Hernando S, Castellano D. García-Donas J, et al. Eur Urol Focus. 2017 Oct;3(4-5):430-436. doi: 10.1016/j.euf.2016.09.004. Epub 2016 Oct 4. Eur Urol Focus. 2017. PMID: 28753791
PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
Roldan-Romero JM, Beuselinck B, Santos M, Rodriguez-Moreno JF, Lanillos J, Calsina B, Gutierrez A, Tang K, Lainez N, Puente J, Castellano D, Esteban E, Climent MA, Arranz JA, Albersen M, Oudard S, Couchy G, Caleiras E, Montero-Conde C, Cascón A, Robledo M, Rodríguez-Antona C, García-Donas J; Spanish Oncology Genitourinary Group (SOGUG). Roldan-Romero JM, et al. Int J Cancer. 2020 Mar 1;146(5):1435-1444. doi: 10.1002/ijc.32579. Epub 2019 Aug 9. Int J Cancer. 2020. PMID: 31335987
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy.
Grande E, Alonso-Gordoa T, Reig O, Esteban E, Castellano D, Garcia-Del-Muro X, Mendez MJ, García-Donas J, González Rodríguez M, Arranz-Arija JA, Lopez-Criado P, Molina-Cerrillo J, Mellado B, Alvarez-Fernandez C, De Velasco G, Cuéllar-Rivas MA, Rodríguez-Alonso RM, Rodríguez-Moreno JF, Suarez-Rodriguez C. Grande E, et al. ESMO Open. 2022 Apr;7(2):100463. doi: 10.1016/j.esmoop.2022.100463. Epub 2022 Apr 8. ESMO Open. 2022. PMID: 35405437 Free PMC article. Clinical Trial.
Addendum: A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial.
de Velasco G, Carril-Ajuria L, Guerrero-Ramos F, Alonso-Gordoa T, Rodríguez-Moreno JF, Carretero A, Martin-Soberon M, de la Rosa-Kehrmann F, Castellano D. de Velasco G, et al. Oncotarget. 2022 Aug 4;13:983. doi: 10.18632/oncotarget.28263. Oncotarget. 2022. PMID: 36455393 Free PMC article. No abstract available.
Case-control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study.
García-Donas J, de Velasco G, Madurga R, Chamorro J, Rosero D, Etxaniz O, Pérez-Gracia JL, Pinto Á, Cacho D, Barba M, Borrega P, Lázaro M, Rodriguez L, Villalobos L, García L, Cuellar A, Solís-Hernández MP, González A, Pernaut C, Rodríguez-Moreno JF. García-Donas J, et al. Among authors: rodriguez moreno jf. Clin Transl Oncol. 2024 Mar;26(3):732-738. doi: 10.1007/s12094-023-03295-2. Epub 2023 Aug 9. Clin Transl Oncol. 2024. PMID: 37556096
Retrospective study assessing the role of the androgen receptor in clear cell renal cell cancer patients treated with VEGFR inhibitors in monotherapy.
Osorio L, Grazioso TP, de Velasco G, Etxaniz O, Pérez-Gracia JL, Pinto Á, Durán I, Grande E, Garcia PB, Lázaro M, Rodriguez L, Villalobos ML, García L, Cuellar A, Solís-Hernández MP, Pernaut C, Rodríguez-Moreno JF, Rodriguez-Antona C, García-Donas J. Osorio L, et al. Among authors: rodriguez moreno jf. Clin Transl Oncol. 2024 Oct 4. doi: 10.1007/s12094-024-03652-9. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39365364
Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01).
Garcia-Donas J, Garrigos L, Lainez N, Santaballa A, Redondo A, Cueva JF, Rubio MJ, Prieto M, Lopez-Guerrero JA, Garcia-Casado Z, Barquin A, Grande E, Alia EG, Sevillano E, Bover I, Grazioso TP, Sanchez-Escribano R, Hurtado A, Navarro P, Rodriguez-Moreno JF. Garcia-Donas J, et al. Among authors: rodriguez moreno jf. Clin Transl Oncol. 2024 Dec 30. doi: 10.1007/s12094-024-03827-4. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39738931
36 results